Files and links (1)
Published, Version of Record (VoR)CC BY-NC-ND V4.0, Open
Journal article
Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer
International journal of gynecological cancer, v 26(4), pp 626-631
01 May 2016
PMID: 27051048
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Objective: Only 3% of patients with epithelial ovarian cancer (EOC) have a longer treatment-free interval (TFI) after second-line intravenous (IV) platinum chemotherapy than with frontline IV therapy. We sought to examine what impact second-line combination IV/intraperitoneal (IV/IP) platinum therapy might have on the ratio of second-line to first-line TFI in patients treated with second-line IP platinum chemotherapy for first recurrence after front-line IV therapy.
Methods: A retrospective analysis of women who received combination platinum-based IV/IP chemotherapy for recurrent EOC between January 2005 and March 2011 was conducted. Patients were identified from the tumor registry, and office records from a large gynecologic oncology practice and patient records were reviewed. The first and second TFIs were defined as the time from the end of previous platinum-based therapy to the start of next therapy.
Results: Twenty-five women received N/IP chemotherapy for their first EOC recurrence after IV chemotherapy. In 10 patients (40%), we observed a longer TFI after N/IP chemotherapy than after primary IV chemotherapy. For these 10 patients, the median TFI for primary response was 22 months (range, 15-28), whereas median TFI after N/IP chemotherapy for recurrent disease was 37 months (range, 12-61).
Conclusions: For EOC patients with limited peritoneal recurrence, 40% of patients had a second-line IP-platinum TFI that exceeded their frontline IV-platinum TFI compared to published data. These data support the use of IV/IP chemotherapy as a treatment for recurrence.
Metrics
Details
- Title
- Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer
- Creators
- Michelle M. Boisen - Magee-Womens HospitalJamie L. Lesnock - Mid Atlantic Gynecol Oncol Mon Gen Hosp, Morgantown, WV USAScott D. Richard - Med Coll Penn & Hahnemann Univ, Dept Gynecol Oncol, Philadelphia, PA 19102 USASushil Beriwal - UPMC, Magee Womens Hosp, Dept Radiat Oncol, Pittsburgh, PA 15213 USAJoseph L. Kelley - UPMC, Magee Womens Hosp, Div Gynecol Oncol, Pittsburgh, PA 15213 USAKristin K. Zorn - Univ Arkansas Med Sci, Div Gynecol Oncol, Little Rock, AR 72205 USARobert P. Edwards - UPMC, Magee Womens Hosp, Div Gynecol Oncol, Pittsburgh, PA 15213 USA
- Publication Details
- International journal of gynecological cancer, v 26(4), pp 626-631
- Publisher
- Bmj Publishing Group
- Number of pages
- 6
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine); Obstetrics and Gynecology
- Web of Science ID
- WOS:000377146600005
- Scopus ID
- 2-s2.0-84965138886
- Other Identifier
- 991019167716104721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Obstetrics & Gynecology
- Oncology